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Prostatic cancer is the second commonest malignancy in men in
developed countries and the second highest cause of cancer death.
Incidence is increasing, partly due to increased rates of diagnosis
due to the use of serum prostate-specific antigen (PSA) testing and
partly due to the increasing age profile in the population. Tumours
are initially sensitive to androgen deprivation, which can provide
effective palliation of symptoms in many cases with locally
advanced or metastatic disease. However, most tumours eventu-
ally become hormone resistant and further systemic therapy is
usually ineffective. There is thus a pressing need for more effec-
tive therapies for this disease. 
The proto-oncogene c-erbB-2/NEU/HER2, is a 185 000 MW
transmembrane protein of the erbB/epidermal growth factor
receptor family with intracellular tyrosine kinase activity.
Inappropriate expression or expression of mutated HER2 protein
results in transformation in mouse models and correlates with poor
prognosis in a variety of human tumours. Overexpression of HER2
is found in 16–83% of cases of prostate cancer assessed by
immunohistochemistry (Ross et al, 1993; Fox et al, 1994; Lyne 
et al, 1997; Morote et al, 1999) and 42–44% assessed by fluore-
scent in situ hybridization (FISH) (Ross et al, 1993, 1997;
Kallakury et al, 1998). In addition, HER2 overexpression corre-
lates with markers of poor prognosis in prostate cancer (Sadasivan
et al, 1993; Fox et al, 1994; Ross et al, 1997; Kallakury et al, 1998;
Morote et al, 1999). Recent data suggests that HER2 overexpres-
sion may functionally contribute to the development of androgen
independence (Craft et al, 1999; Yeh et al, 1999). 
There is increasing interest in therapeutic approaches based on
HER2 following the results obtained in breast cancer therapy with
Herceptin (Cobleigh et al, 1998; Slamon et al, 1998). We report
preliminary results with an anti-HER2 ´ anti-CD64 bispecific
antibody in HER2-positive hormone refractory prostate cancer. 
Bispecific antibodies (BsAbs) are chemically linked or geneti-
cally engineered fusion products of either whole or Fab´ fragments
of 2 monoclonal antibodies (mAbs). MDX-H210 is constructed
from the murine mAb 520C9, which recognizes HER2, and the
humanized murine mAb H22, which recognizes the high-affinity
type I Fc receptor CD64 (FcgR1), present on monocytes/
macrophages and activated neutrophils. In vitro, MDX-H210
effectively induces antibody-dependent cellular cytotoxicity
against HER2 positive targets (Fanger et al, 1992). The binding
site for MDX-H210 on the CD64 molecule is distinct from that of
IgG and there is no competition for the receptor from endogeneous
antibody (Guyre et al, 1989). We chose to combine the antibody
with the cytokine GM-CSF as preliminary phase I studies had
shown the combination to be well tolerated (Posey et al, 1999).
Preclinical studies have shown that GM-CSF can augment mono-
cyte anti-tumour function, enhance in vitro monocyte (Metcalf,
1986) and granulocyte (Kushner and Cheung, 1989) antibody-
directed cellular cytotoxicity, and increase expression of CD64
(Connor et al, 1990). 
We have previously reported preliminary results using an inter-
mittent schedule of treatment with a 3-week ‘rest period’ after
each 3 week of dosing period (James et al, 1998). This trial
showed that a number of patients had initial PSA responses but
that PSA values rose during the rest period. The treatment was
well tolerated. The present study reports results using a continuous
dosing schedule in a similar patient group. The primary objective
of the study was to assess the activity of the combination of 
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MDX-H210 and GM-CSF and to evaluate the safety and tolera-
bility of the combination with continuous treatment. 
PATIENTS AND METHODS 
Patients 
Patients with hormone refractory adenocarcinoma of the prostate
were eligible for inclusion. A maximum of 2 prior regimens of
hormonal manipulation (drug therapy or surgery) for treatment of
metastatic disease were permitted, with orchidectomy counting as
1 of the 2 endocrine manipulations. All prior radiation therapy and
surgery must have been completed at least 6 weeks before pro-
tocol therapy and the patient fully recovered from any toxicity.
Hormonal treatment was continued (e.g., Lupron) except for
flutamide or bicalutamide which were discontinued for at least
6 weeks prior to MDX-H210 therapy. Patients were evaluated for
a withdrawal response 6 weeks after cessation of non-steroidal
anti-androgen perior to entering the study. 
Tumour biopsies had to show overexpression of the HER2
as detailed below. Other eligibility criteria included: adequate
haematological, hepatic, and renal function, > 18 years of age,
ECOG performance status 0 or 1, life expectancy > 6 months, and
serum PSA >50 ng ml–1 or <50 ng ml–1 and rising on 3 separate
occasions over the previous 12 months. All patients gave written
informed consent. 
Baseline investigations included imaging as indicated by
disease state including bone scan on all patients, quality of life
assessment and pain scores, 12 lead ECG, full blood count,
biochemical profile, coagulation profile, urinalysis, human anti-
bispecific antibody (HABA) levels and serum PSA levels. 
Immunohistochemistry 
Immunohistological staining for HER2 was done on formalin-
fixed, paraffin wax-embedded tumour. These were usually
sections of material taken at the time of original diagnosis, often
years before treatment. Sections were boiled in 0.01 M citrate
buffer pH 6.0 for 30 minutes in a microwave oven. Endogenous
peroxidase was blocked with 0.5% hydrogen peroxide in
methanol. Rabbit antiserum to HER2 (Dako) was used at 1:25.
Biotinylated goat antiserum to rabbit immunoglobulins (Dako
Duet) at 1:100 and streptavidin-biotin-peroxidase complex (Dako
Duet) at 1:100 were the second and third stages. Peroxidase
was detected with 1% tetra-aminobiphenyl hydrochloride
(diaminobenzidine) with 0.01% hydrogen peroxide. Positive
staining was defined as staining of the cell membrane of most
viable cells in the cancer. Sections could be separated into
unequivocally positive or unequivocally negative. A control
section of carcinoma with positive staining was included in every
batch. 
Treatment 
Patients were treated with GM-CSF (Monograstim, Schering
Plough in the UK or Leukine, Immunex in the USA) 5 mg kg–1
day–1 by subcutaneous injection for 4 days plus MDX-H210
15 mg m–2 by intravenous infusion on day 4, repeated weekly for
6 weeks. Patients were reassessed during the final week of each
cycle. Patients with stable disease or better were eligible for
further cycles of treatment. A dose modification schedule was
included in the protocol but no patient required dose modification
during the study period. 
Pain scores 
Pain scores were assessed using the Wisconsin Brief Pain
Questionnaire which uses a scale from 0 (‘no pain at all’) to 10
(‘pain as bad as you can imagine’). Patients with evaluable pain
had to have an average score ³1 for 1 cycle. 
Response criteria 
Response assessment in prostate cancer is problematical as
patients rarely have objectively assessable tumour masses.
Response to treatment was assessed at the end of each 6 week
cycle. A pain response was defined as a mean 2-point decrease or
1-point if baseline score was 1. A PSA response was defined as
³50% fall from baseline which has been shown to be of prognostic
significance (Smith et al, 1998) and is felt by most investigators
to be clinically meaningful (Dawson, 1998). Toxicity was assessed
using the NCI Clinical Toxicity Grading (CTG) system. In addi-
tion, changes in PSA velocity (Vollmer et al, 1998) in the pre study
and on study period were compared where adequate pre study PSA
data were available. 
Statistical considerations 
Patients completing one cycle of treatment (6 weeks) were eligible
for the efficacy analysis. All patients receiving treatment were
included in the toxicity analysis. Data was censored on 25
November 1998. Response and toxicity data were analysed with
simple descriptive statistics. In addition, PSA relative velocity was
analysed using the formula of Vollmer et al (Vollmer et al, 1998). 
Survival curves were calculated according to the method of
Kaplan and Meier (Kaplan and Meier, 1958) and the log-rank test
(Peto et al, 1977) used to assess differences between response
groups. 
RESULTS 
Patient characteristics 
25 patients entered the trial and are included in the safety analysis.
Mean age was 65 (range 55–79) years. Prior therapy included
palliative chemotherapy (6 patients), radiotherapy (9 patients) and
radical prostatectomy (3 patients). Patient characteristics,
including prior therapy are shown in Table 1. Overall, 76% of
patients screened were HER2 positive. Tumours fell into 2 groups
and with either all or nearly all cells positive or none or hardly any
cells positive. 
Toxicity 
The majority of patients experienced only grade 1–2 toxicity, prin-
cipally flu-like symptoms such as low-grade fevers, myalgia and
sweats. These were generally self-limiting and either required no
therapy or simple analgesia such as paracetamol. There were 10
adverse events of grade 3 or 4 rated as definitely, probably or
possibly due to the treatment (Table 2). There were no treatment-
related deaths. 5 patients completed less than 1 cycle of treatment;
1 for personal reasons, 1 developed heart failure on commencing154 ND James et al
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GM-CSF and did not receive MDX-H210; 2 patients had severe
allergic reactions (anaphylactic and bronchospasm) and 1 left for
disease progression after 2 weeks. These patients are not included
in the analysis of efficacy. 
There was no relationship between HABA titres and response or
toxicity. Maximum toxicity with infusion of MDX-H210 generally
occurred with the first infusion (with one exception, see Table 1),
with little or no toxicity on rechallenge, a phenomenon also
observed with other antibody therapies (Cobleigh et al, 1998;
McLaughlin et al, 1998; Slamon et al, 1998) and previously
reported by us with the intermittent antibody infusion schedule
(James et al, 1998). 
Treatment efficacy 
All patients included in the efficacy analysis completed at least 1
cycle of treatment. 7 patients of 20 (35%) evaluable patients had a
PSA reduction of >50%, ranging from 51% to 99%, with duration
of PSA reductions of 50% or greater from entry into the study at
the censor date being 71, 83, 89, 122, 128, 160+ and 184+ days. In
addition, a further 6 patients experienced minor PSA responses
(<50%, >25% reduction in PSA) of 41, 89+, 131, 140, 152 and 165
days duration. Patients with less than 25% reduction in PSA or
progression <25% from baseline remained on treatment for 23, 27,
29, 38, 53 and 141+ days. 6 of 12 (50%) patients with evaluable
pain have had improvements in pain scores (7–4, 6–0, 4–1, 1–0,
1–0, 1–0). All had reductions in PSA of >25%. Responses lasted
for 1 cycle (1 patient), 2 cycles (2 patients), 3 cycles (2 patients), 4
cycles (1 patient) and 12 cycles (1 patient). No patient developed
new bone lesions on treatment. Withdrawal was for PSA progres-
sion. No patient had complete resolution of bone lesions.
Treatment was discontinued in 17 patients for progression, 3 for
toxicity, 2 refused further treatment, 2 for other reasons. One
patient continued on treatment at the censor date. 
The PSA relative velocity was calculated for the period prior to
study entry and for the period on study (Vollmer et al, 1998) and is
shown in Figure 1. The PSA velocity on therapy decreased in
15/18 (83%) patients with sufficient pre-study PSA data (paired 
t-test for pre-treatment vs. post-treatment PSA relative velocity 
P (two tailed) = 0.0006). This effect was most marked in the
responding patients. 
DISCUSSION 
Patients with hormone-refractory prostate cancer are among the
most challenging to treat in oncology. In this setting, MDX-H210
plus GM-CSF has shown clinical benefit, with a highly acceptable
therapeutic index and this study we believe is amongst the first
evidence of clinical responses to immunotherapy in prostate
cancer. We had in addition seen PSA responses >50% in 5/18
patients treated with an intermittent schedule of the 2 drugs (3
weeks on, 3 weeks off). In that study, a proportion of patients
experienced a rise in PSA in the rest period, but little toxicity on
treatment. Treatment-related toxicity in the first study was
predominantly grade 0–2 with patients able to tolerate prolonged
dosing as in the present study (James et al, 1998). Accordingly, it
was decided to proceed with the continuous therapy regimen
described in this paper. Similar results have been reported using a
slightly different GM-CSF schedule (Small et al, 1999) but only
1 patient experienced a PSA fall >50% sustained for >6 weeks.
In contrast, an immunotherapy study by Slovin et al of an 131
I-labelled anti-TAG72 plus interferon-g failed to show any
activity (Slovin et al, 1998). 
The results clearly demonstrate a high frequency of clinically
significant reductions in PSA that were durable in nature. 35% of
the patients treated had greater than 50% reductions in PSA levels
in response to treatment. 63% of patients continued to be treated
for 77 days or more without disease progression or with continued
reductions in PSA levels. No patient developed clinical features of
disease progression whilst the PSA level had fallen below base-
line. In addition, as can be seen from Figure 1, the average PSA
velocity during the period on therapy decreased in all except for 3
patients. All patients with pain score improvements had falls in
PSA of at least 25%. Patients remained on treatment until either
disease progression or toxicity resulted in withdrawal. 
Table 1 Patient characteristics and prior therapy 
Age (y) Median (range) 67.0 (54–78) 
Race 
Caucasian 22 (88.0%) 
Black 2 (8.0%) 
Hispanic 1 (4.0%) 
ECOG performance status 
0 17 (68.0%) 
1 7 (28.0%) 
2 1 (4.0%) 
Duration of cancer diagnosis
median (range) 2.70 (0.8–9.4) y 
Prior systemic cancer therapy: 
None 1 (4.0%) 
Yes 24 (96.0%) 
Chemotherapy 6 (25.0%) 
Hormonal 23 (95.8%) 
Immunotherapy 0 
Other 6 (25.0%) 
Prior radiation: 
None 9 (36.0%) 
Yes 16 (64.0%) 
Prior surgery: 
None 3 (12.0%) 
Yes 22 (88.0%) 
Figure 1 PSA velocity calculated for the period prior to commencing
treatment and compared to the period on treatment with GM-CSF and
MDX-H210.
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The quality of life evaluation revealed that two-thirds of those
treated either had significant improvement in their pain, had no
new pain if there was no pain at baseline, or had no worsening of
their pain. The treatment regimen was well tolerated, with only 2
patients withdrawing from the study because of adverse events,
one due to GM-CSF and one due to MDX-210 but associated with
underlying disease progression. 
The combination regimen evaluated was initially designed
because of evidence of an in vitro interaction between the bispe-
cific antibody and GM-CSF (Fanger et al, 1992), so the combina-
tion with the antibody seemed logical to maximize the possibility
of clinical response. Since the trial commenced, studies have
reported evidence of direct clinical activity for GM-CSF in
prostate cancer (Simons et al, 1998; Small et al, 1999). The results
of the combination are thus in part due to GM-CSF and we are
currently carrying out a phase II study to assess the activity of the
antibody alone. 
In conclusion, evidence is presented of clinical responses in
patients with hormone refractory prostate carcinoma. Toxicity was
generally mild to moderate and mostly manageable on an out-
patient basis. Further studies of regimens containing MDX-H210
and GM-CSF are indicated in prostate cancer. 
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